PMID- 27867016
OWN - NLM
STAT- MEDLINE
DCOM- 20170905
LR  - 20180414
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 388
DP  - 2017 Mar 1
TI  - Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via 
      activation of transforming growth factor beta 1 and hypoxia dependent repression of 
      GATA-binding factor 3.
PG  - 187-197
LID - S0304-3835(16)30704-2 [pii]
LID - 10.1016/j.canlet.2016.11.016 [doi]
AB  - Vasohibin 2 (VASH2) is identified as an angiogenic factor, and has been 
      implicated in tumor angiogenesis, proliferation and epithelial-mesenchymal 
      transition (EMT). To investigate the EMT role of VASH2 in breast cancer, we 
      overexpressed or knocked down expression of VASH2 in human breast cancer cell 
      lines. We observed that VASH2 induced EMT in vitro and in vivo. The transforming 
      growth factor beta1 (TGFbeta1) pathway was activated by VASH2, and expression of a 
      dominant negative TGFbeta type II receptor could block VASH2-mediated EMT. In 
      clinical breast cancer tissues VASH2 positively correlated with TGFbeta1 expression, 
      but negatively correlated with E-cadherin (a marker of EMT) expression. Under 
      hypoxic conditions in vitro or in vivo, we found that down-regulation of estrogen 
      receptor 1 (ESR1) in VASH2 overexpressing ESR1 positive cells suppressed 
      E-cadherin. Correlation coefficient analysis indicated that VASH2 and ESR1 
      expression were negatively correlated in clinical human breast cancer tissues. 
      Further study revealed that a transcription factor of ESR1, GATA-binding factor 3 
      (GATA3), was down-regulated by VASH2 under hypoxia or in vivo. These findings 
      suggest that VASH2 drives breast cancer cells to undergo EMT by activation of the 
      TGFbeta1 pathway and hypoxia dependent repression GATA3-ESR1 pathway, leading to 
      cancer metastasis.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Tu, Min
AU  - Tu M
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Li, Zhanjun
AU  - Li Z
AD  - Department of Vascular & Herniary Surgery, The People's Hospital of Liaoning 
      Province, PR China.
FAU - Liu, Xian
AU  - Liu X
AD  - Invasive Technology Department, Jining No. 1 People's Hospital, PR China.
FAU - Lv, Nan
AU  - Lv N
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Xi, Chunhua
AU  - Xi C
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Lu, Zipeng
AU  - Lu Z
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Wei, Jishu
AU  - Wei J
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Song, Guoxin
AU  - Song G
AD  - Department of Pathology, The First Affiliated Hospital with Nanjing Medical 
      University, PR China.
FAU - Chen, Jianmin
AU  - Chen J
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Guo, Feng
AU  - Guo F
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Jiang, Kuirong
AU  - Jiang K
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China.
FAU - Wang, Shui
AU  - Wang S
AD  - Department of General Surgery, The First Affiliated Hospital with Nanjing Medical 
      University, PR China.
FAU - Gao, Wentao
AU  - Gao W
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China. Electronic address: gao11@hotmail.com.
FAU - Miao, Yi
AU  - Miao Y
AD  - Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 
      PR China. Electronic address: miaoyi@njmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161117
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Angiogenic Proteins)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (VASH2 protein, mouse)
SB  - IM
MH  - Angiogenic Proteins/*genetics/metabolism
MH  - Animals
MH  - Breast Neoplasms/*genetics/pathology
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - GATA3 Transcription Factor
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Transforming Growth Factor beta1/*metabolism
OTO - NOTNLM
OT  - Epithelial-mesenchymal transition
OT  - GATA-Binding factor 3
OT  - Human breast cancer
OT  - Transforming growth factor beta 1
OT  - Vasohibin 2
EDAT- 2016/11/22 06:00
MHDA- 2017/09/07 06:00
CRDT- 2016/11/22 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/11/02 00:00 [revised]
PHST- 2016/11/10 00:00 [accepted]
PHST- 2016/11/22 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2016/11/22 06:00 [entrez]
AID - S0304-3835(16)30704-2 [pii]
AID - 10.1016/j.canlet.2016.11.016 [doi]
PST - ppublish
SO  - Cancer Lett. 2017 Mar 1;388:187-197. doi: 10.1016/j.canlet.2016.11.016. Epub 2016 
      Nov 17.